NUVASIVE INC (NUVA) Fundamental Analysis & Valuation

NASDAQ:NUVA • US6707041058

39.75 USD
-0.91 (-2.24%)
At close: Aug 31, 2023
39.88 USD
+0.13 (+0.33%)
After Hours: 8/31/2023, 8:10:26 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Forecast Earnings Financials Ownership News

This NUVA fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

Fundamental Rating

4

Taking everything into account, NUVA scores 4 out of 10 in our fundamental rating. NUVA was compared to 184 industry peers in the Health Care Equipment & Supplies industry. While NUVA is still in line with the averages on profitability rating, there are concerns on its financial health. NUVA is not valued too expensively and it also shows a decent growth rate.


Dividend Valuation Growth Profitability Health

5

1. NUVA Profitability Analysis

1.1 Basic Checks

  • NUVA had positive earnings in the past year.
  • In the past year NUVA had a positive cash flow from operations.
NUVA Yearly Net Income VS EBIT VS OCF VS FCFNUVA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 0 50M -50M 100M 150M 200M

1.2 Ratios

  • Looking at the Return On Assets, with a value of 1.36%, NUVA is in the better half of the industry, outperforming 75.38% of the companies in the same industry.
  • With a decent Return On Equity value of 3.19%, NUVA is doing good in the industry, outperforming 76.38% of the companies in the same industry.
  • NUVA has a better Return On Invested Capital (3.43%) than 76.38% of its industry peers.
  • NUVA had an Average Return On Invested Capital over the past 3 years of 2.87%. This is significantly below the industry average of 9.15%.
  • The last Return On Invested Capital (3.43%) for NUVA is above the 3 year average (2.87%), which is a sign of increasing profitability.
Industry RankSector Rank
ROA 1.36%
ROE 3.19%
ROIC 3.43%
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)2.87%
ROIC(5y)3.87%
NUVA Yearly ROA, ROE, ROICNUVA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 0 5 -5 10

1.3 Margins

  • Looking at the Profit Margin, with a value of 2.32%, NUVA is in the better half of the industry, outperforming 74.37% of the companies in the same industry.
  • In the last couple of years the Profit Margin of NUVA has declined.
  • NUVA has a Operating Margin of 6.73%. This is in the better half of the industry: NUVA outperforms 74.87% of its industry peers.
  • In the last couple of years the Operating Margin of NUVA has declined.
  • NUVA's Gross Margin of 71.66% is amongst the best of the industry. NUVA outperforms 82.41% of its industry peers.
  • In the last couple of years the Gross Margin of NUVA has remained more or less at the same level.
Industry RankSector Rank
OM 6.73%
PM (TTM) 2.32%
GM 71.66%
OM growth 3Y-12.51%
OM growth 5Y-9.94%
PM growth 3Y-15.55%
PM growth 5Y-15.81%
GM growth 3Y-0.57%
GM growth 5Y-0.5%
NUVA Yearly Profit, Operating, Gross MarginsNUVA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 0 20 40 60

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

2

2. NUVA Health Analysis

2.1 Basic Checks

  • With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), NUVA is destroying value.
  • NUVA has more shares outstanding than it did 1 year ago.
  • The debt/assets ratio for NUVA has been reduced compared to a year ago.
NUVA Yearly Shares OutstandingNUVA Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 10M 20M 30M 40M 50M
NUVA Yearly Total Debt VS Total AssetsNUVA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 500M 1B 1.5B 2B 2.5B

2.2 Solvency

  • An Altman-Z score of 1.91 indicates that NUVA is not a great score, but indicates only limited risk for bankruptcy at the moment.
  • The Altman-Z score of NUVA (1.91) is comparable to the rest of the industry.
  • A Debt/Equity ratio of 0.89 indicates that NUVA is somewhat dependend on debt financing.
  • NUVA's Debt to Equity ratio of 0.89 is on the low side compared to the rest of the industry. NUVA is outperformed by 78.89% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.89
Debt/FCF N/A
Altman-Z 1.91
ROIC/WACC0.42
WACC8.11%
NUVA Yearly LT Debt VS Equity VS FCFNUVA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 200M 400M 600M 800M

2.3 Liquidity

  • NUVA has a Current Ratio of 1.25. This is a normal value and indicates that NUVA is financially healthy and should not expect problems in meeting its short term obligations.
  • NUVA's Current ratio of 1.25 is on the low side compared to the rest of the industry. NUVA is outperformed by 89.45% of its industry peers.
  • A Quick Ratio of 0.65 indicates that NUVA may have some problems paying its short term obligations.
  • With a Quick ratio value of 0.65, NUVA is not doing good in the industry: 93.97% of the companies in the same industry are doing better.
Industry RankSector Rank
Current Ratio 1.25
Quick Ratio 0.65
NUVA Yearly Current Assets VS Current LiabilitesNUVA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 500M 1B 1.5B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

5

3. NUVA Growth Analysis

3.1 Past

  • NUVA shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 15.61%, which is quite good.
  • Measured over the past 5 years, NUVA shows a small growth in Earnings Per Share. The EPS has been growing by 0.62% on average per year.
  • The Revenue has been growing slightly by 4.44% in the past year.
  • The Revenue has been growing slightly by 3.20% on average over the past years.
EPS 1Y (TTM)15.61%
EPS 3Y-7.23%
EPS 5Y0.62%
EPS Q2Q%19.15%
Revenue 1Y (TTM)4.44%
Revenue growth 3Y0.96%
Revenue growth 5Y3.2%
Sales Q2Q%2.36%

3.2 Future

  • NUVA is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 14.32% yearly.
  • Based on estimates for the next years, NUVA will show a small growth in Revenue. The Revenue will grow by 6.89% on average per year.
EPS Next Y13.97%
EPS Next 2Y14.82%
EPS Next 3Y14.9%
EPS Next 5Y14.32%
Revenue Next Year6.01%
Revenue Next 2Y6.22%
Revenue Next 3Y6.45%
Revenue Next 5Y6.89%

3.3 Evolution

  • When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
  • The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
NUVA Yearly Revenue VS EstimatesNUVA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 500M 1B 1.5B
NUVA Yearly EPS VS EstimatesNUVA Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 1 2 3

More info and screens

Find the best growth stocksShow best growing peers

4

4. NUVA Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings ratio is 19.88, which indicates a rather expensive current valuation of NUVA.
  • Based on the Price/Earnings ratio, NUVA is valued cheaply inside the industry as 86.93% of the companies are valued more expensively.
  • The average S&P500 Price/Earnings ratio is at 26.15. NUVA is valued slightly cheaper when compared to this.
  • A Price/Forward Earnings ratio of 15.23 indicates a correct valuation of NUVA.
  • 88.44% of the companies in the same industry are more expensive than NUVA, based on the Price/Forward Earnings ratio.
  • The average S&P500 Price/Forward Earnings ratio is at 24.27. NUVA is valued slightly cheaper when compared to this.
Industry RankSector Rank
PE 19.88
Fwd PE 15.23
NUVA Price Earnings VS Forward Price EarningsNUVA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30

4.2 Price Multiples

  • Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of NUVA indicates a rather cheap valuation: NUVA is cheaper than 93.47% of the companies listed in the same industry.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 11
NUVA Per share dataNUVA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 10 15 20

4.3 Compensation for Growth

  • The PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
  • A more expensive valuation may be justified as NUVA's earnings are expected to grow with 14.90% in the coming years.
PEG (NY)1.42
PEG (5Y)32.2
EPS Next 2Y14.82%
EPS Next 3Y14.9%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. NUVA Dividend Analysis

5.1 Amount

  • No dividends for NUVA!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

Find the best dividend stocksShow peers with best dividend

NUVA Fundamentals: All Metrics, Ratios and Statistics

NUVASIVE INC

NASDAQ:NUVA (8/31/2023, 8:10:26 PM)

After market: 39.88 +0.13 (+0.33%)

39.75

-0.91 (-2.24%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)08-02
Earnings (Next)11-07
Inst Owners0%
Inst Owner Change0%
Ins Owners1.99%
Ins Owner Change0%
Market Cap2.08B
Revenue(TTM)1.23B
Net Income(TTM)28.45M
Analysts70.91
Price Target50.72 (27.6%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)4.04%
Min EPS beat(2)0.41%
Max EPS beat(2)7.68%
EPS beat(4)2
Avg EPS beat(4)-2.68%
Min EPS beat(4)-17.19%
Max EPS beat(4)7.68%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)-1.05%
Min Revenue beat(2)-3.26%
Max Revenue beat(2)1.16%
Revenue beat(4)1
Avg Revenue beat(4)-2.23%
Min Revenue beat(4)-3.74%
Max Revenue beat(4)1.16%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)1.53%
PT rev (3m)2.05%
EPS NQ rev (1m)0%
EPS NQ rev (3m)1.88%
EPS NY rev (1m)0%
EPS NY rev (3m)2.33%
Revenue NQ rev (1m)-0.02%
Revenue NQ rev (3m)-0.63%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE 19.88
Fwd PE 15.23
P/S 1.7
P/FCF N/A
P/OCF 14.94
P/B 2.34
P/tB 24.74
EV/EBITDA 11
EPS(TTM)2
EY5.03%
EPS(NY)2.61
Fwd EY6.57%
FCF(TTM)-0.06
FCFYN/A
OCF(TTM)2.66
OCFY6.69%
SpS23.38
BVpS17.02
TBVpS1.61
PEG (NY)1.42
PEG (5Y)32.2
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA 1.36%
ROE 3.19%
ROCE 5.48%
ROIC 3.43%
ROICexc 3.59%
ROICexgc 6.59%
OM 6.73%
PM (TTM) 2.32%
GM 71.66%
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)2.87%
ROIC(5y)3.87%
ROICexc(3y)4.12%
ROICexc(5y)4.87%
ROICexgc(3y)17.94%
ROICexgc(5y)16.07%
ROCE(3y)3.71%
ROCE(5y)5.01%
ROICexgc growth 3Y3.59%
ROICexgc growth 5Y-1.31%
ROICexc growth 3Y-7.11%
ROICexc growth 5Y-4.99%
OM growth 3Y-12.51%
OM growth 5Y-9.94%
PM growth 3Y-15.55%
PM growth 5Y-15.81%
GM growth 3Y-0.57%
GM growth 5Y-0.5%
F-Score7
Asset Turnover0.59
Health
Industry RankSector Rank
Debt/Equity 0.89
Debt/FCF N/A
Debt/EBITDA 3.58
Cap/Depr 101.93%
Cap/Sales 11.65%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.25
Quick Ratio 0.65
Altman-Z 1.91
F-Score7
WACC8.11%
ROIC/WACC0.42
Cap/Depr(3y)82.61%
Cap/Depr(5y)85.69%
Cap/Sales(3y)10.64%
Cap/Sales(5y)10.6%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)15.61%
EPS 3Y-7.23%
EPS 5Y0.62%
EPS Q2Q%19.15%
EPS Next Y13.97%
EPS Next 2Y14.82%
EPS Next 3Y14.9%
EPS Next 5Y14.32%
Revenue 1Y (TTM)4.44%
Revenue growth 3Y0.96%
Revenue growth 5Y3.2%
Sales Q2Q%2.36%
Revenue Next Year6.01%
Revenue Next 2Y6.22%
Revenue Next 3Y6.45%
Revenue Next 5Y6.89%
EBIT growth 1Y45.07%
EBIT growth 3Y-11.68%
EBIT growth 5Y-7.06%
EBIT Next Year96.6%
EBIT Next 3Y33.66%
EBIT Next 5Y25.87%
FCF growth 1Y-102.72%
FCF growth 3Y-34.34%
FCF growth 5Y-14.37%
OCF growth 1Y-39.92%
OCF growth 3Y-10.42%
OCF growth 5Y-0.91%

NUVASIVE INC / NUVA FAQ

What is the fundamental rating for NUVA stock?

ChartMill assigns a fundamental rating of 4 / 10 to NUVA.


What is the valuation status for NUVA stock?

ChartMill assigns a valuation rating of 5 / 10 to NUVASIVE INC (NUVA). This can be considered as Fairly Valued.


Can you provide the profitability details for NUVASIVE INC?

NUVASIVE INC (NUVA) has a profitability rating of 6 / 10.


Can you provide the PE and PB ratios for NUVA stock?

The Price/Earnings (PE) ratio for NUVASIVE INC (NUVA) is 19.88 and the Price/Book (PB) ratio is 2.34.


What is the earnings growth outlook for NUVASIVE INC?

The Earnings per Share (EPS) of NUVASIVE INC (NUVA) is expected to grow by 13.97% in the next year.